PSMA7 and Schnyder corneal dystrophy: In preclinical trials for SCD, clinical trials based on in vivo HSPC gene editing, such as Exa‐Cel, OTQ923, and EDIT‐301, have the potential to overcome the limitations of in vitro gene editing and to provide minimally invasive and cost‐effective gene therapies that show promise for use in the treatment of SCD patients in low‐ and middle‐income countries.488